Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Combining atezolizumab to neoadjuvant chemotherapy does not improve pathologic complete response rates for TNBC patients

Share :

SABCS 2019
Published: 18 Dec 2019
Views: 845
Rating:
Save
Dr Luca Gianni - San Raffaele Hospital, Milan, Italy

Dr Luca Gianni gives a press conference at the 2019 San Antonio Breast Cancer Symposium about the combination of atezolizumab with neoadjuvant chemotherapy for the treatment of triple-negative breast cancer (TNBC).

Watch our interview with Dr Luca Gianni here.

Read more about the study here. 

Related Videos

Targeted therapies associated with increased risk for and incidence of thrombosis in the treatment of breast cancer

Dr James Martin - Cleveland Clinic, Cleveland, USA
Targeted therapies associated with increased risk for and incidence of thrombosis in the treatment of breast cancer ( Dr James Martin - Cleveland Clinic, Cleveland, USA )
20 Dec 2024

Comment: Trial updates from GALAXIES Lung-201 and RELATIVITY-104 in NSCLC

Dr Marina Garassino - University of Chicago, Chicago, USA
Comment: Trial updates from GALAXIES Lung-201 and RELATIVITY-104 in NSCLC ( Dr Marina Garassino - University of Chicago, Chicago, USA )
26 Sep 2024

ESMO 2024: Highlights and analysis

Assoc Prof Bishal Gyawali - Queen's University, Kingston, Canada
ESMO 2024: Highlights and analysis ( Assoc Prof Bishal Gyawali - Queen's University, Kingston, Canada )
16 Sep 2024

ESMO 2024: Latest in EGFR mutated NSCLC

Prof Ignacio Gil-Bazo, Dr Mariana Brandão, Prof Benjamin Besse and Prof Enriqueta Felip
ESMO 2024: Latest in EGFR mutated NSCLC ( Prof Ignacio Gil-Bazo, Dr Mariana Brandão, Prof Benjamin Besse and Prof Enriqueta Felip )
16 Sep 2024

ESMO 2024: Optimising the personalisation of prostate cancer treatment

Prof Alison Birtle, Dr Alejo Rodríguez-Vida, Dr Pasquale Rescigno and Prof Gunhild von Amsberg
ESMO 2024: Optimising the personalisation of prostate cancer treatment ( Prof Alison Birtle, Dr Alejo Rodríguez-Vida, Dr Pasquale Rescigno and Prof Gunhild von Amsberg )
15 Sep 2024

Adjuvant avelumab versus control does not significantly improve DFS but does improve OS in high-risk TNBC patients

Prof Pier Conte - University of Padova, Padova, Italy
Adjuvant avelumab versus control does not significantly improve DFS but does improve OS in high-risk TNBC patients ( Prof Pier Conte - University of Padova, Padova, Italy )
3 Jun 2024

OncoAlert round up July 28th to August 3rd, 2023

Dr Gil Morgan - Executive Director, OncoAlert
OncoAlert round up July 28th to August 3rd, 2023 ( Dr Gil Morgan - Executive Director, OncoAlert )
4 Aug 2023

Management of HER2 positive metastatic breast cancer treatment algorithm

Prof Sandra Swain - Georgetown University Medical Center, Washington DC, USA
Management of HER2 positive metastatic breast cancer treatment algorithm ( Prof Sandra Swain - Georgetown University Medical Center, Washington DC, USA )
31 Jan 2023

Post neoadjuvant management in BRCA mutant breast cancer patients

Prof Banu Arun - MD Anderson Cancer Center, Houston, USA
Post neoadjuvant management in BRCA mutant breast cancer patients ( Prof Banu Arun - MD Anderson Cancer Center, Houston, USA )
31 Jan 2023

More from ecancer

Register with ecancer to receive our newsletter

Register here

Explore patient resources at ecancerpatient

Visit site

Find out more about ecancer and the work we do

About ecancer

Support ecancer's work by making a donation